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IncreaaedQT IntervalDispersionFollowing
Peat-DialvticDecreaaeof Potassiumand
Magnesi~m:A Modelto Studythe Repolarizatlon
ChangesAssociatedto ElectrolyteAbnormalities
E.H. Loeati, G. Bagliani, M. Stramba-Badiale, P.Saronio, M. Timio. Cerdro
Fisiologia Clinica a Ipartensione, Univof Milan and Nephrology Unit,
Foligno Hospital, Italy
In patients with chronic renal diaease requiring recui’rent hemodialysis (HD),
a marked decrease of serum K+ and Mg+2between the pre- and post-dialytic
phases is obaetved, often associated with onset of cardiac arrhythmias. The
effect of K+ and Mg+2gradients on ECG profile was studied in 20 consecutive
HD patients (17 males, mean age51 +17 years), with the following exclusion
criteria: 1) Coronary artery disease; 2) NYHA class >2 or ejection fraction
.40%, 3) Ventricular hypertrophy; 4) LBBB or RBBB; 5) Atrial fibrillation.
Serum ‘mncentrations (mEq/L) of K+, Mg+2, Na+, Ca+2, and Cl- were
monitored, and absolute QT duration (msec), mrrected QT interval (QTc,
msec), and two repolafizstion dispersion indexes: QTc fmax-min(msec) and
dispersion coefficient (DC = OTCstandard deviatiordmean C?TCx 100) were
measured from 12-lead ECGSin pre- and post-dialytic phaaes.
K+ f@+2 Q~ QTc QTcmax-min DC
Pre-diaiysis 5.2+ 0.8 2.8+ 0.6 352+32 399+26 53+21 4.6+ 1,5
Post-dialysis 3.5& 0.6 2.1+ 0.4 374k 59 428k 38 69k 65 7.2+ 4.9
pvalues <0.0001 < 0.000t 0.05 0.0005 0.01 0.01
Thua, the peridialytic K+ and Mg+2 gradienta induce a significant in-
creaae in QT duration and dispersion of ventricular repolarization, with major
changea in T and U wave morphology. The association between serum
electrolytes changes and abnormalities of ventricular depolarization might
contribute to the understanding of the ionic basia involved in QT interval
prolongation.
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El7381 EarlyandPredischargeAepirinAdministrationAmongPatientsWithSuspsctedAcuteMyocardial
Infarction:CurrentClinicalPracticeinthe United
States
M. Burns, R.C. Becker, J.M. Gore, C. Lambrew, W. French, W. Rogers, for
the National Regisby of Myooardial Infarction (NRMI-2) Investigators.
Univeraily of Massachusatfs Medical School, Worcestefi MA, USA
Aspirin (ASA), a widely available, inexpensive, and well-tolerated platelet
inhibitor, is recommended for patients with acute coronary syndromes, in-
cluding myocarrfial infarction (Ml). We determined early (<24 hours) and
prediacharge ASA adminiatrstion among 220,171 patients with suspect%
Ml. Recipients (n= 165,122) (74.9%) were younger, more often male, arrived
at the hoapitsl earfier,and were more Iikelytobe Killip Class Iorll (p < 0.001).
Patients treated with thrombolytiee (n = 67,564), PTCA (n = 14,395) and no
reperfusion (n = 137,468) received ASA 90%, 62%, and 67% of the time,
respectively. By logistic regression analysis independent predictors of early
ASA use included ST segment elevation (OR 1.41; 1.17-1.69; p = 0.0001)
and male sex (OR 1.28; 1.11-1.46; p =0.0001). Prior Ml (OR 0.74; 0.62-0.66;
p = 0.0001), previous bypasa grafting (OR 0.76; 0.61-0.95; p = 0.02) and
not low-risk categorization were inveraely associated with early ASA use.
In-hospital recurrent Ml (OR 0.94; 0.62-0.99; p = 0.04), atroke (OR 0.73;
0.67-0.68; p = 0.0001) and death (OR 0.24; 0.22-0.26; p = 0.0001) were
significantly reduced among earty ASA users. Nearly one-third of patients
surviving their Ml did not receive ASAat hospital discharge. We conclude that
ASA ia currently underutilized in routine clinical practice as a primary or ad-
junotive form of therapy in Ml, especially among patients at risk for recurrent
thrombotic events. ASAforseoondary prevention may also be underutilized.
National ef70rtsto increaae ASA use should improve the standard of care.
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CooperativeCardiovascularProject(CCP)-
Underuseof QualityIndicatorsforAcuteMyocardlal
InfarctioninMedicarePatientsin NewYorkState
M. Malach, R.P.Nenner, /PRO, Lake Success, NY USA
A national Cooperative Cardiovascular Project (CCP) under the direction
of The Health Care Financing Administration (HCFA) assessed the care of
hospitalized patienta with acute myccardial infarctions (AMI) during an eight
month period of 1994. Nationally there were 220,000 with 17,000 in New York
(NY). As a result of chart abstractions, the data clearly auggeat that there are
significant opportunities for improvement in hospital based care.
AMI is a leading cause of death, The project was to demonstrate compli-
ance with ten quality indicator for AMI, arrived at by an American College
of Cardiology (ACC) Task Force with HCFA. Increased compliance would
improve the outcome of AMI care especially in medicare patienta. Three
cruciai quality indicators – aspirin, beta blockers and timely thrombolytics
were used noticeably Ieaa in the older and the sicker patients. New York
mortality for AMI of 16.2% (nationally 18.6Yo)can be explained by a median
age of 75 and 48% anterior AMIs. The benefits of ACE inhibitors for low left
ventricular ejection fraction and the non-use of calcium channel blockers was
documented. Data for the 10 indicators will be presented.
IPRO has provided each of 205 hospitals with their data and peer and
national comparisons and conducted regional meetings and teleconferences
to review the repotis and methods of increasing compliance with the ten
quality indicators..Successful examples of quality improvement programs
with protocols and care mapa will be presented. Outcome improvement for
AMI in medicare’patientsare expected on new reviews in succeeding months.
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1738-31Theparadigmf~rAnti-plateletEffectonContinuous
12-LeadST-SegmentRecoveryinAcuteMl
M.W. Krucoff, R.A. Barrington, D.J. Moliterno, C.L. Green, K.M. Trollinger,
A. Kristinsson, C.D. Morgan, J. Burks, T. Nygaard, J.E. Pope, E.J. Topol,
R.M. Califf. Duke University Medica/ CenteL Durham, NC, USA
Parameters of continuous 12-lead ST-segment recovety correlate with an-
giographic patency, therapeutic drug effect and clinical outcomes. In the
PARADIGM study the effects of the anti-platelet agent Iamifiban (150-400
kg bolus, 1-2 @rein infusion) randomized vs. placebo in pts with <6 hra
cheat pain & ST elevation given tPA and ASA were assesaed with con-
tinuous 12-lead ST-segment recovery analysis in 244 pts with analyzable
data. ST parameters included presenca of >50% ST recovery at 90 min
(ST-PATENCY);time to ST recovety stable for >4 hrs (STABLE); total ST
deviation curve area (AREA); and re-elevation >150wVafter STABLE (LATE
ST). Results were, as% or median (25th, 75th % ile):
Parameter Placebo Lamifiban P-value
# PTS 7e 165
eOMinST.Patency 63°A 60”/6 0.007
STABLE(rein) 130(45,253) 89 (31,149) 0.0039
AREA(uV-min) 6256(1370,13390) 4736(O,10123) 0.028
LATEST 240/n 12% 0.026
Thua, even with a fairly small sample size, the desirable effects of platelet
inhibition with Iamifiban are evident compared to placebo, with a 30-50%
reduction in continuous ST parameters of reperfusion speed, atability, total
infarct “burden” and recurrent ischemia.
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R lntrav~n~us.rgstrobenversus~eParinas
co-medicationto altepleeeinthetreatmentof acute
myocardialinfarction;preliminaryresultsof the
ARGAMIpilotstudy
F.Vermeer, A. Vahanian, P.W.FeIs, P.Besse, D. Radzik, M.L. Simoons,
Acadamic Hospital Maastricht, University of Limburg, Tha Netherlands
Intravenous argatroban (a new synthetic thrombin inhibitor derived from
arginine) was compared to heparin as co-medication to altepiaae in the
treatment of patients with acute myocardial infarction in a 2:1 double blind,
randomized trial using a double dummy technique. Argatroban was given aa
a bolua of 100 @kg prior to the starl of thrombolytic therapy, followed by an
infusion of 3 @kg/rein. Heparin was given as a bolus of 5000 IU, followed
by an infuaion of 1000 IiJ/hour, titrated against (a)PTT. Alteplase was given
according to the accelerated regimen as used in GUSTO. Acute coronary
angiography was scheduled for all pts at 90 min after atart of the infusion and
after 5 to 10 days.
